FDA Investigator Christine M Whitby, CSO

Christine M Whitby, CSO has conducted inspections on 24 sites in 2 countries as of 12 Dec 2022. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
24
Last Inspection Date:
12 Dec 2022
Investigator Role:
FDA Investigation Participant
Redica ID:
100005422
Countries of Inspections:
United States of America, Canada
FDA Investigators that have inspected at least one site in common with Christine M Whitby, CSO:
Alan C Gion, Allen F Hall, Ana P Barido, Anthony C Warchut, Barbara J Holladay, Barbara Janine Breithaupt, Barbara M Frazier, Brunilda Torres, Byungja E Marciante, Candice C Mandera, Candice J Cortes, Carl J Montgomery, Carla C Tuite, Carol Rivera Lopez, PhD, Catherine Whiteside, PhD, CDR Rochelle B Young, RPh, MSA, Chaltu Nwakijra, Charles A Snipes, PhD, Charles M Kerns, BLT DO, Charles R Bonapace, PhD, Chris J Drabick, Christian D Lynch (CDL), Christopher Janik, Chunsheng Cai, PhD, Constance Lewin, MD, Ct Viswanathan, PhD, Cynthia A Harris, MD, RN, Cynthia Jim, CSO, Daniel R Azar, Darin S Wiegers, David K Glasgow, David L Chon, Debra Bower, Diane C Thibodeau, Dien N Nguyen, Douglas A Campbell, Dr. Abhijit Raha, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Earl Echon, Edmund F Mrak, Jr, Edward J Janik, Eleanor M Felton, Emest F Bizjak, Emmanuel A Dimaano, Jr, Erin L Mcfiren, Erin M Mcdowell, Gabrielle J Swain, Hang N Guo, Hector Jcolon Torres, Iris C Macinnes, Jacqueline A O'shaughnessy, PhD, Jacqueline Mdiaz Albertini, Jeanne D Shaffer, Jennifer A Longie Vollom, John A Kadavil, PhD, John Dan, John J Welsh, PhD, John Kadavil, PhD, Jonah S Ufferfilge, Joseph L Despins, PhD, Julie D Bringger, Jyoti B Patel, PhD, Karen M Kondas, Kenneth Nieves, Kent A Conforti, Kurt A Brorson, PhD, Lakisha M Williams, Larry K Austin, Lori S Lawless, LT Melanie M Mayor, USPHS, Lynette P Salisbury, Margaret M Annes, Margaret M Sands, Mark R Mcclain, Martin K Yau, PhD, Marya F Ricks, Matthew C Watson, Matthew M Henciak, Maya M Davis, Melissa J Garcia, Miah Jung, Michael F Skelly, PhD, Michelle M Noe Varga, Mildred L Mccray, Nealie C Newberger, Nebil A Oumer, Nilufer M Tampal, PhD, Nina Yang, Norman K Starks, Peter R Lenahan, Philip J Snoy, Rachel C Harrington, Rapti D Madurawe, Richard Heath Coats, Robert C Steyert, Robert L Hummel, Ronald T Nowalk, Rose Ashley, Ruark Lanham, Sam Pepe, Sherry L Secrist, BLT DO, Sripal R Mada, PhD, Stephanie L Shapley, Stephanie Mangigian, MS/OSH, RN, Stephen R Souza, Steven J Thurber, Steven P Donald, Susan J Essenmacher, Susan M Jackson, Tamika E Allen, RN, Toyin B Oladimeji, Tracy L Taras, PhD, Victoria M Daddeo, William H Linkroum, Zhongren Wu

Christine M Whitby, CSO's Documents

Publish Date Document Type Title
January, 2001 EIR Covance Laboratories, Inc. - EIR, 2001-01-11
June, 2000 FDA 483 Response Shabazz, Lloyd A - Form 483R, 2001-03-02
February, 2000 FDA 483 Response Euclid Systems Corporation - Form 483R, 2000-03-01
June, 2000 EIR Montag, Thomas W. - EIR, 2000-06-23
September, 2000 FDA 483 American Histolabs Inc - Form 483, 2000-09-25
November, 2018 EIR Pfizer Laboratories Div Pfizer Inc - EIR, 2018-11-02
June, 2001 FDA 483 Response BioReliance Corporation - Form 483R, 2001-07-05
April, 2000 EIR Rusinowitz, Martin S., M.D. - EIR, 2000-04-25
June, 2000 EIR Shabazz, Lloyd A - EIR, 2000-06-23
April, 2000 FDA 483 Rusinowitz, Martin S., M.D. - Form 483, 2000-04-25
April, 2001 EIR BIOCON, Incorporated - EIR, 2001-04-27
August, 2001 EIR Ore Pharmaceuticals Inc - EIR, 2001-08-15
June, 2003 FDA 483 Biovail Contract Research - Form 483, 2003-06-13
June, 2001 FDA 483 BioReliance Corporation - Form 483, 2001-06-22
July, 2001 EIR Charles River Laboratories Inc. - EIR, 2001-07-25
August, 2001 FDA 483 Ore Pharmaceuticals Inc - Form 483, 2001-08-15
August, 2001 FDA 483 Response Ore Pharmaceuticals Inc - Form 483R, 2001-08-22
June, 2000 FDA 483 Shabazz, Lloyd A - Form 483, 2000-06-23
February, 2000 FDA 483 Euclid Systems Corporation - Form 483, 2000-02-16
June, 2000 FDA 483 Shabazz, Lloyd A - Form 483, 2000-06-23
June, 2001 EIR BioReliance Corporation - EIR, 2001-06-22
February, 2000 EIR Euclid Systems Corporation - EIR, 2000-02-16
September, 2000 EIR American Histolabs Inc - EIR, 2000-09-25

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more